Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Study to Explore the Effect of SP-624 on Brain Network Analytics in Cohorts of Healthy Adult Subjects and Subjects With Major Depressive Disorder

NCT06570369 is registered in ClinicalTrials.gov with Sirtsei Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06570369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Study to Explore the Effect of SP-624 on Brain Network Analytics in Cohorts of Healthy Adult Subjects and Subjects With Major Depressive Disorder
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 22, 2024
Completion date
May 18, 2026
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

depression, healthy, major depressive disorder